<DOC>
	<DOCNO>NCT02140554</DOCNO>
	<brief_summary>This non-randomized , open label , multi-site , single-dose , Phase 1 study 29 adult severe sickle cell disease ( SCD ) . The study evaluate safety efficacy LentiGlobin BB305 Drug Product [ consist autologous CD34+ hematopoietic stem cell ( HSC ) transduce LentiGlobin BB305 lentiviral vector encode human beta A-T87Q-globin gene ] .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy LentiGlobin BB305 Drug Product Severe Sickle Cell Disease</brief_title>
	<detailed_description>Subject participation study 2 year post-treatment . Subjects enroll study ask participate subsequent long-term follow study monitor safety efficacy treatment receive 13 year post-transplant .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 . 18 year age old . 2 . Diagnosis sickle cell disease ( SCD ) , either βS/βS βS/β0 βS/β+ genotype . 3 . Have severe SCD . i.e. , set appropriate supportive care measure SCD ( e.g. , pain management plan , hydroxyurea ) , judge Investigator , experience one follow event : Recurrent severe vaso occlusive crisis ( VOC ) ( least 2 episode per year precede 2 year 2 year prior initiation regular transfusion program ) . Acute Chest Syndrome ( ACS ) ( least 2 total episode prior 2 year , least one episode past year year prior initiation regular transfusion program ) , define acute event pneumonialike symptom presence new pulmonary infiltrate . History overt stroke , define sudden neurologic change last 24 hour accompany cerebral MRI change . Echocardiographic evidence tricuspid regurgitant jet velocity ( TRJV ) &gt; 2.5 m/s . 4 . Medically eligible undergo hematopoietic stem cell transplant ( HSCT ) . 5 . Karnofsky performance status ≥ 60 . 6 . Subjects determine investigator physical limitation undergo general anesthesia provide adequate bone marrow harvest bilateral postsuperior iliac site . 1 . Positive presence human immunodeficiency virus type 1 2 ( HIV 1 HIV 2 ) . 2 . Positive active infection . 3 . Any major organ dysfunction ( renal , liver , lung cardiac abnormality ) . 4 . Inadequate bone marrow function , define absolute neutrophil count &lt; 1000/µL ( &lt; 500/µL subject hydroxyurea treatment ) platelet count &lt; 150,000/µL . 5 . Moyamoya disease cerebral MRI . Subjects history revascularization procedure Moyamoya disease ( e.g. , encephaloduroarteriosynangiosis ( EDAS ) procedure ) eligible procedure occur &gt; 1 year prior study entry . 6 . Contraindication anesthesia bone marrow harvest . 7 . Any prior current malignancy immunodeficiency disorder , except previously treat , nonlife threatening , cure tumor squamous cell carcinoma skin . 8 . Prior receipt allogeneic transplant . 9 . Immediate family member know suspected Familial Cancer Syndrome 10 . Pregnancy , breastfeed postpartum female , absence adequate contraception fertile subject . 11 . Participation another clinical study investigational drug within 30 day Screening . 12 . Prior receipt gene therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>